Cure Alzheimer's Fund Cure Alzheimer's Fund

Neuroimmune Consortium: Biomarker Tool Development

2022

A well-recognized hallmark of Alzheimer’s disease (AD) is the activation of the brain’s immune system, sometimes called neuroinflammation. Despite having detailed information about neuroinflammation in AD from pathology samples after death, we have very limited tools for understanding neuroinflammation at the early stages of AD in living people. To address this need, we are developing imaging agents for use in positron emission tomography (PET) that will help characterize neuroinflammation.

Jacob Hooker NEUROINFLAMMATION Studies of Innate Immune Pathology Translational

Funding to Date

$287,500

Focus

Studies of Innate Immune Pathology, Translational

Researchers

Jacob Hooker, Ph.D.

Related Content:


Probing the Molecular Underpinnings of G Protein-Coupled Receptor ADGRG1 Mediated Protective Microglial Responses to Alzheimer’s disease Xianhua Piao 2024-10-31 Multidimensional Profiling of TREM2-Mutated or APOE4-mutated Microglia in Human Brain Organoids to Understand Dysregulated Microglia Neuronal Crosstalk in Alzheimer’s Disease Florent Ginhoux 2024-10-31 Impact of DNA Damage-Mediated Stimulator of Interferon Genes (STING) Activation on Myelin Function in an Alzheimer’s Disease Animal Model Alban Gaultier 2024-09-24 Targeting Reactive Astrocytes AMPK Signaling to Suppress Inflammation in Alzheimer’s Disease Gilbert Gallardo 2024-09-16 Contributions of IL34 Signaling to Microglial Function and Alzheimer’s Pathology in Mice Staci Bilbo 2024-09-16 Meningeal Regulatory T-Cells (Tregs) in Individuals with Versus without Alzheimer’s Disease Diane Mathis 2024-09-16 Elucidating Mechanisms Driving the Compromised Balance Between Mitophagy and cGAS-STING-Initiated Inflammation Towards a Treatment for Alzheimer’s Disease Per Nilsson Evandro F. Fang 2024-08-22 Investigating Alzheimer’s Disease-Associated Membrane Biology in Microglia and Neurons Anna Greka Beth Stevens 2024-05-31